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Medicine, Cambridge, UKA B S T R A C TBackground: There is uncertainty about the cost effectiveness of
early intensive treatment versus routine care in individuals with type
2 diabetes detected by screening. Objectives: To derive a trial-
informed estimate of the incremental costs of intensive treatment
as delivered in the Anglo-Danish-Dutch Study of Intensive Treatment
in People with Screen-Detected Diabetes in Primary Care-Europe
(ADDITION) trial and to revisit the long-term cost-effectiveness
analysis from the perspective of the UK National Health Service.
Methods: We analyzed the electronic primary care records of a
subsample of the ADDITION-Cambridge trial cohort (n ¼ 173). Unit
costs of used primary care services were taken from the published
literature. Incremental annual costs of intensive treatment versus
routine care in years 1 to 5 after diagnosis were calculated using
multilevel generalized linear models. We revisited the long-term cost-
utility analyses for the ADDITION-UK trial cohort and reported results
for ADDITION-Cambridge using the UK Prospective Diabetes Study
Outcomes Model and the trial-informed cost estimates according to a
previously developed evaluation framework. Results: Incremental
annual costs of intensive treatment over years 1 to 5 averaged
£29.10 (standard error ¼ £33.00) for consultations with generalee front matter & 2017 Published by Elsevier Inc.
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ndence to: Simon J. Grifﬁn, Medical Research Coun
nstitute of Metabolic Science, Cambridge Biomedipractitioners and nurses and £54.60 (standard error ¼ £28.50) for
metabolic and cardioprotective medication. For ADDITION-UK, over
the 10-, 20-, and 30-year time horizon, adjusted incremental quality-
adjusted life-years (QALYs) were 0.014, 0.043, and 0.048, and adjusted
incremental costs were £1,021, £1,217, and £1,311, resulting in incre-
mental cost-effectiveness ratios of £71,232/QALY, £28,444/QALY, and
£27,549/QALY, respectively. Respective incremental cost-effectiveness
ratios for ADDITION-Cambridge were slightly higher. Conclusions:
The incremental costs of intensive treatment as delivered in the
ADDITION-Cambridge trial were lower than expected. Given UK
willingness-to-pay thresholds in patients with screen-detected dia-
betes, intensive treatment is of borderline cost effectiveness over a
time horizon of 20 years and more.
Keywords: ADDITION trial, cost effectiveness, intensive treatment,
screen-detected diabetes.
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Diabetes mellitus is an increasing public health problem, associ-
ated with costly micro- andmacrovascular complications, reduced
quality of life, and premature death [1–4]. The direct and indirect
societal costs of diabetes in the United Kingdom are expected to
rise from £22 billion in 2010 to £35 billion in 2030, and a large share
of this ﬁnancial burden is attributable to the treatment of diabetic
complications in patients with type 2 diabetes [5]. Cost-effective
disease management strategies are therefore needed to diminish
the burden of the disease on patients and health care systems.
Previous research has shown that intensive multifactorial
treatment, including management of cardiovascular risk factorsand glycemic control, reduces the risk of cardiovascular events
and is an effective and cost-effective intervention for patients
with long-standing diabetes [6–8]. There is also solid evidence
that tight control of glucose and blood pressure in newly
routinely diagnosed patients is an effective and cost-effective
strategy [9–11]. Conversely, little is known about the cost-
effectiveness of intensive treatment in individuals with type 2
diabetes detected by screening who, all else being equal, will
typically be at an earlier stage in the disease.
The diagnosis of diabetes in routine care settings occurs on
average a couple of years after physiological onset [12]. Because
of improvements in quality of care and ongoing considerations
about population-based screening, this lead time is expected toon behalf of International Society for Pharmacoeconomics and
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.
cil Epidemiology Unit, University of Cambridge School of Clinical
cal Campus, Cambridge CB2 0QQ, UK.
V A L U E I N H E A L T H 2 0 ( 2 0 1 7 ) 1 2 8 8 – 1 2 9 8 1289decrease, resulting in a large number of patients who could
potentially beneﬁt from early intensive treatment.
The pragmatic cluster-randomized Anglo-Danish-Dutch Study
of Intensive Treatment in People with Screen-Detected Diabetes
in Primary Care-Europe (ADDITION) trial studied the effect of
intensive multifactorial treatment compared with routine care on
cardiovascular morbidity and mortality in individuals with type 2
diabetes detected by screening [13,14]. The results showed a
nonstatistically signiﬁcant relative risk reduction in the incidence
of the composite cardiovascular end point over a time horizon of
5 years [15].
Of note, levels of cardiovascular risk factors improved mod-
estly over the 5 years of the trial, and a modeling study using the
UK Prospective Diabetes Study (UKPDS) risk equations indicated
that the cardiovascular risk might be reduced in the long- term
[15,16]. Despite this, an initial cost-effectiveness analysis using
the UKPDS outcomes model incorporating conservative protocol-
driven intervention cost estimates showed that over a time
horizon of 30 years, the intervention was not cost effective
according to current UK willingness-to-pay (WTP) thresholds
(incremental cost-effectiveness ratio [ICER] £37,500 per quality-
adjusted life-year [QALY] vs. WTP thresholds of £20,000–£30,000)
[17], albeit with substantial decision uncertainty (31% probability
that the ICER is o£30,000). Nevertheless, as we know from a
previous study that the adherence of general practitioners (GPs)
to the trial protocol was not perfect, the incremental costs of the
intervention actually delivered might have been lower than
expected [18]. Therefore, although our outcomes assessment
would be valid, we may have overestimated the incremental
cost. Had the intensive treatment regimen been highly cost-
effective or cost-ineffective and with a high degree of certainty,
further exploration would have been of no value. Nevertheless,
given the proximity of the ICER to the (upper) threshold and the
level of decision uncertainty, we felt further investigation into the
intervention costs was justiﬁed.
The objective of this study was therefore to estimate the
incremental costs of early intensive treatment as delivered in
ADDITION using empirical data from electronic primary care
records. We then used this new information to update our
previous estimate of the long-term (10–30 years) cost-
effectiveness analysis of the ADDITION intervention in the
United Kingdom from a National Health Service (NHS) perspec-
tive, in a manner consistent with an iterative approach to
research and decision making [19–21].Methods
Study Design and Study Population
The ADDITION-UK (NCT00237549) study was a part of the
ADDITION-Europe study and consisted of two phases—a screen-
ing program and a pragmatic, cluster-randomized trial compar-
ing the effect of early intensive treatment with that of routine
care in individuals with type 2 diabetes detected by screening on
a composite end point of cardiovascular morbidity and mortality
[13,14]. High-risk individuals without known diabetes aged 40 to
69 years registered in 69 primary care surgeries within a range of
100 miles of the study centers in Cambridge and Leicester were
invited for stepwise screening. Of these, 867 individuals (from 49
surgeries) from Cambridge and 159 individuals (from 20 surgeries)
from Leicester with type 2 diabetes detected by screening par-
ticipated in the primary care–based intervention study (ADDI-
TION-UK). Two participants withdrew before year 5, leaving a
total study size of 1024 participants. Details of the study protocol
including assessment of primary end points and inclusion and
exclusion criteria have been published elsewhere [15]. The studywas approved by local ethics committees, and all participants
provided informed consent.
Routine Care versus Intensive Treatment
Patients were treated according to the treatment allocation of
their surgery. Patients in the routine care arm in Leicester and
Cambridge received diabetes care through the UK NHS on the
basis of contemporary UK treatment guidelines [22–24]. In the
intensive treatment arm, additional features were added to
routine care. Some of these intensive treatment features differed
between the Leicester and the Cambridge GP surgeries.
In Leicester, intensive treatment was delivered by a specialist
team of doctors, nurses, and dieticians within peripatetic com-
munity clinics according to the Diabetes Education and Self-
Management Programme, which is a group education program
delivered by two registered health care professionals in one
6-hour session [25]. The curriculum focuses on lifestyle changes
and medication adherence using theories of efﬁcient goal setting
and self-efﬁcacy. In addition, in the ﬁrst year after diagnosis,
patients were offered bimonthly appointments with a nurse or a
GP in a community peripatetic clinic, and 4-monthly thereafter.
In Cambridge, primary care surgeries received funding for
more frequent contacts between patients and practitioners. An
initial practice-based academic detailing session conducted by a
local diabetologist and an academic GP and interactive practice-
based audit and feedback sessions were organized around 6 and
14 months after the initial education session and annually
thereafter. Surgery staff received theory-based education materi-
als to hand over to patients, and participants were encouraged to
initiate lifestyle changes, to adhere to medication schemes, to
self-monitor blood glucose levels if given a glucometer by their
practice, and to attend annual health checks.
In addition, in all intensive treatment arm surgeries (Leicester
and Cambridge), GPs were advised to follow treatment algorithms
for medication with glucose-lowering, angiotensin-converting
enzyme inhibiting, lipid-lowering, and platelet-inhibiting medi-
cation that were slightly tighter than those in contemporary UK
treatment guidelines [13,22–24]. According to the protocol, ther-
apy with glucose-lowering medication was indicated for patients
with a glycated hemoglobin A1c (HbA1c) level of more than 6.5%,
therapy with angiotensin-converting enzyme inhibitors was
indicated for patients with blood pressure higher than 120/80
mm Hg or prevalent cardiovascular disease, statin therapy was
indicated for patients with a cholesterol level of higher than
3.5 mmol/L, and aspirin therapy was indicated for all patients
without speciﬁc contraindications [14].
Incremental Costs of Intensive Treatment in
ADDITION-Cambridge
Data source and operationalization
Because of the high cost of assessing and extracting data from
electronic primary care records, it was decided in the planning
phase of the study that only the records of a subset of the study
would be assessed. Records of each participant with a primary
end point (i.e., cardiovascular event) plus the records of two
random participants from the same GP surgery without a primary
end point within the 5-year trial period were accessed. Conse-
quently, the records of 30 participants with a primary end point
and of 60 participants without a primary end point from the
intensive treatment arm and the records of 33 participants with a
primary end point and of 66 participants without a primary end
point from the routine care arm were accessed.
These records comprised information on consultations with
outpatient health care professionals, prescribed medications, and
diagnostic tests from the date of diagnosis (between 2002 and
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total). Costs associated with the use of these services were
obtained by multiplying the number of consumed resources by
their respective unit prices. Unit prices for consultations with GPs
and nurses were extracted from the Personal Social Services
Research Unit report on unit costs of health and social care [26].
Prices for all other consultations were taken from the National
Schedule of Reference Costs 2009–10 for NHS Trusts [27]. The
Prescription Cost Analysis 2010 was used to assign unit prices for
prescribed medications [28]. Because of incomplete or ambiguous
information from the free-text records, no unit costs could be
assigned to around 1% of the recorded used resources. These
services were therefore priced according to the mean unit price of
used units for the person and year.
On the basis of the study protocol, we allocated cost items to
the following categories:1. costs for consultations related to the trial protocol (contacts
with GPs and nurses);2. costs for medication related to the trial protocol (glucose-
lowering drugs, blood pressure–lowering drugs, cholesterol-
lowering drugs, and platelet-inhibiting drugs); and3. costs for all other services (contacts with other primary health
care professionals and outpatient specialists, other medica-
tions, and diagnostic tests).
Statistical analyses
In the long-term decision model, costs for primary care and
medication accrue until a person dies. As input parameters for
this decision model, one therefore needs an empirical estimate
that describes the difference in average costs between a person
alive in the intensive treatment arm and a person alive in the
routine care arm. For this, we subdivided the 5-year analysis
period into ﬁve annual intervals (year 1 to year 5 after diagnosis)
and included the observation year in which a person died, but
excluded subsequent years from the analysis. After exclusion of
16 participants for whom none or less than 1 year’s data were
available, 173 participants (from 34 surgeries; mean cluster size ¼ 5;
minimum ¼ 2, maximum ¼ 17) provided 841 person-years of data
until death. Medication data were missing for 18 of the 173. These
costs were imputed with Markov chain Monte-Carlo procedures
using model covariates and available annual cost values for
consultations, medications, and diagnostic tests. This yielded a
ﬁnal analysis sample of 173 participants with 841 complete
observation years.
Here, we ﬁrst descriptively reported the resource utilization of
categories 1 and 2, which has been described in detail elsewhere
[18]. Second, we analyzed the annual incremental costs of
intensive treatment for each resource utilization category sepa-
rately using generalized linear models (GLMs). We tested a GLM
with identity-link and Gaussian distribution (i.e., ordinary least-
squares model), a GLM with log-link and gamma/Poisson distri-
bution, and a GLM with square-root-link and gamma/Poisson
distribution (in models with a log link, all zero costs were set to a
nominal £1) [29]. Results from these models were very similar; for
overall costs, we decided to use the ordinary least-squares model,
which is the simplest and yielded the most conservative cost
estimates [30]. Models accounted for observation years being
clustered into patients and patients being clustered into primary
care surgeries (three-level random intercept model) and were
adjusted for age, sex, and HbA1c level at diagnosis. We also
introduced an interaction term between the year after diagnosis
and the treatment status to capture potential trends over time. In
a second step, using the same statistical methods, we estimated
the total annual incremental costs. To account for the non-
random selection of the analyzed subsample, we introduced ageneral weighting factor, representing the inverse probability of
being included in this analysis, on the basis of the status of
having a primary end point [31].
These models yielded mean estimates and standard
errors (SEs) for the annual incremental costs of consultations
(βconsultations-Cambridge; SEconsultations-Cambridge), medication
(βmedication-Cambridge; SEmedication-Cambridge), and the intervention
as a whole, including other primary care services (βtotal-Cambridge;
SEtotal-Cambridge). Analyses were performed with SAS 9.3 using the
GLIMMIX, MI, and MIANALYZE procedures (SAS Institute, Inc.,
Cary, NC).
Long-Term Cost Effectiveness of Intensive Treatment in
ADDITION-UK/Cambridge
The long-term cost effectiveness of ADDITION used the outputs
from the UKPDS model as per the original model, with the
updated short-term intervention costs from the electronic pri-
mary care records. The methods are brieﬂy described here. The
analysis is conducted from the perspective of the NHS. Because
we have empirical data on the intervention costs only from the
Cambridge centers but not from the Leicester centers, we ﬁrst
update the previous cost-effectiveness analyses for ADDITION-UK
(Leicester and Cambridge). In a second step we report a
separate long-term cost-effectiveness analysis for ADDITION-
Cambridge only.
Quality-adjusted life-years
The UKPDS outcomes model v1.3 was applied to simulate the
individual accumulated QALYs of patients [17,32]. The UKPDS
Outcomes Model is a widely used individual-level state transition
simulation model (i.e., a microsimulation model) based on data
from a UK population and applicable for the given evaluation
context [33]. Its performance has been tested against the ADDITION
5-year outcomes in a previous study showing a moderate calibra-
tion and discrimination [34]. The model predicts future events
(ischemic heart disease, myocardial infarction, heart failure, stroke,
amputation, blindness, and renal failure) and death as a function of
several values at diagnosis of diabetes (e.g., sex, ethnicity, and
duration of diabetes) and on the basis of values of risk factors at
diagnosis and in subsequent years (e.g., smoking, body mass index,
cholesterol, high-density lipoprotein, HbA1c level, and systolic
blood pressure). Results on risk factor changes and effects on
micro- and macrovascular events over the 5-year observation
period have been reported previously and are summarized in
Appendix 1 in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2017.05.018 [15–17,35]. Utility decrements associated
with the modeled events were obtained from the published
literature, and the additive method was used for patients with
multiple events (see Appendix 2 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2017.05.018) [36–38].
Costs
We assumed that the costs for patients in the intensive treat-
ment arm comprise the costs of treatment of complications plus
the costs of delivering the intervention itself, including costs for
planning and implementation and for extra consultations and
medication, whereas in the routine care arm, only the costs of the
treatment of complications occur. All costs were calculated in
British pounds for the price year 2009/2010. The price year was
chosen to maintain comparability with the previous economic
analysis [17].
Treatment of events/complications. As for the effects, we used
the UKPDS outcomes model v1.3 to estimate the per-patient costs
for the treatment of events and complications [32]. Unit costs for
Table 1 – Protocol-based and empirical cost estimates (£) used in the initial [17] and updated base-case
cost-effectiveness analyses.
Cost component Center Per protocol* Trial-based†
Accumulated Annually Accumulated Annually
Mean SE Mean SE Mean SE Mean SE
Upfront costs
Planning and implementation Cambridge (n ¼ 452) 375.1 – – – 375.1 0.0 – –
Leicester (n ¼ 61) 71.2 – – – 71.2 0.0 – –
Years 1–5‡
Extra consultations Cambridge (n ¼ 452) 311.3§ – 62.3|| – 145.5 161.5 29.1¶ 32.3¶
Leicester (n ¼ 61) 880.1§ – 176.0|| – 880.1 976.9# 176.0 195.4#
Extra medication Cambridge (n ¼ 452) 262.5 – 52.5 – 273.0 142.5 54.6¶ 28.5¶
Leicester (n ¼ 61) 262.5 – 52.5 – 262.5 137.0# 52.5 27.4#
Year 6 until …
end of observation period death or end of observation period
Extra medication (years 6–10) Cambridge (n ¼ 452) 199.6** – 52.5 – 183.7†† 95.9 54.6¶ 28.5¶
Leicester (n ¼ 61) 199.6** – 52.5 – 203.4†† 106.2# 52.5 27.4#
Extra medication (years 6–20) Cambridge (n ¼ 452) 509.1** – 52.5 – 386.9†† 201.9 54.6¶ 28.5¶
Leicester (n ¼ 61) 509.1** – 52.5 – 434.9†† 227.0# 52.5 27.4#
Extra medication (years 6–30) Cambridge (n ¼ 452) 728.5** – 52.5 – 444.3†† 231.9 54.6¶ 28.5¶
Leicester (n ¼ 61) 728.5** – 52.5 – 520.3†† 271.6# 52.5 27.4#
SE, standard error.
* Protocol-based cost estimates according to the internal accounting of Tao et al. [17].
† Empirical cost estimates according to the analysis on a subsample of the ADDITION sample.
‡ Accumulated costs described without discounting.
§ Costs were assumed to occur from years 1 to 3.
|| Annual costs if distributed over 5 y.
¶ ßs and SEs extracted from Table 3.
# SEs in Leicester were assumed to be proportional to the ones in patients from Cambridge.
** Calculated using
Ptime horizon
t¼6
β annual medication cost ðtÞ
ð1 þ 0:035Þt .
†† Calculated using
PLE
t¼6
β annual medication cost tð Þ
ð1 þ 0:035Þt , where modeled life expectancy (LE) for the 10-, 20-, and 30-y time horizons averaged 9.4, 15.2, and
17.0 y in Cambridge and 9.6, 16.3, and 19.3 y in Leicester.
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study and other published literature (see Appendix 2 in
Supplemental Materials) [37–39]. Again, the additive method
was used to calculate costs in case of multiple complications or
events.
Planning and implementation. The previously published inter-
nal accounting showed average per-patient costs of £375 in
Cambridge and £71 in Leicester for the planning and implemen-
tation (teaching and feedback sessions) of the study [17]. These
values were also used in this analysis.
Extra consultations and medication. For Cambridge (n ¼ 867), we
used the empirically derived cost estimates (βconsultations-Cambridge,
SEconsultations-Cambridge, βmedication-Cambridge, and SEmedication-Cambridge).
For Leicester (n ¼ 159), no empirical cost data were available, and
we used the cost estimates from the internal accounting [17],
which were used for the protocol-based cost-effectiveness
analysis [17]: βconsultations-Leicester (annual per-patient costs for
extra consultations in years 1–5) ¼ £880/5 ¼ £176 and
βmedication-Leicester (annual per-patient costs for extra medication in
years 1–5 and thereafter) ¼ £52.5. A detailed description of the
protocol-based cost estimates is presented in Table 1.
Statistical analysis
For patients in both trial arms, the individual 10-, 20-, and 30-year
accumulated QALYs and costs for the treatment of complications
were projected by running simulations with 1000 inner modelloops and 100 bootstraps of the UKPDS outcomes model v.1.3
with a cycle length of 1 year [32]. Both costs and QALYs
were discounted at a rate of 3.5% according to the guidelines of
the National Institute for Health and Care Excellence (NICE) [40].
Some minor adjustments to the input data were performed
before running the model: Patients with unknown or unclassiﬁ-
able ethnicity were excluded from the analysis (n ¼ 25),
and values of atrial ﬁbrillation, peripheral vascular disease,
ischemic heart disease, congestive heart failure, amputation,
blindness, and renal failure, which were not collected in
ADDITION, were set to 0. Furthermore, missing values of
input variables were imputed via Markov chain Monte-Carlo
procedures (n ¼ 5 imputations), and means and SEs were
subsequently derived using Rubin’s rules (information on the
missing data is provided in Appendix 3 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2017.05.018).
As a base-case scenario, we calculated the incremental cost-
effectiveness for ADDITION-UK, including patients from Cam-
bridge and Leicester. To the simulated costs for the treatment of
complications that occur in both treatment arms, for patients in
the intervention arm, we added the per-patient mean costs for
planning and implementation of the intervention, the discounted
per-patient mean costs for extra consultations in years 1 to 5
P5
t¼1
βconsultations ðtÞ
ð1 þ 0:35Þt
 
, and the discounted per-patient mean costs for
medication until death
PLE
t¼1
βmedication tð Þ
ð1 þ 0:035Þt
 
. Life expectancy (LE) for
the 10-, 20-, and 30-year time horizons averaged approximately
9, 15, and 17 years, respectively. SEs of the different cost
components were summed in an additive manner. In parallel to
Table 2 – Baseline characteristics of the ADDITION population trial cohort.
Characteristic ADDITION-UK
(Cambridge þ Leicester)*
ADDITION-Cambridge analysis subsample
(weighted†)
IT (n ¼ 513) RC (n ¼ 511) IT (n ¼ 82) RC (n ¼ 91)
Primary endpoint during follow-up period (%) 7.2 7.5 6.8 7.7
Sex, female (%) 36.6 40.7 40.8 39.4
Age (y), mean  SD 61.1  7.2 60.1  7.5 61.8  7.3 61  7.1
BMI, mean  SD (kg/m2) 33.1  5.6 33.0  5.9 33.4  5.2 34  5.7
Total cholesterol (mmol/L), mean  SD 5.3  1.1 5.5  1.2 5.4  1.1 5.6  1.2
HDL (mmol/L), mean  SD 1.17  0.4 1.2  0.3 1.2  0.3 1.2  0.3
Systolic blood pressure (mm Hg), mean  SD 142.0  20.1 143.1  19.4 141.6  21 142.5  20.6
HbA1c (%), mean  SD 7.3  1.7 7.3  1.7 7.7  2.2 7.4  1.7
BMI, body mass index; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; IT, intensive treatment; RC, routine care.
* Of the total sample (1026), 2 withdrew from the study.
† Weighting factor: inverse probability of being included in the study on the basis of the status of having a primary end point.
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SEs of QALYs and costs at patient level were used to conduct a
bootstrap analysis (n ¼ 500) adjusting for center, age at diagnosis,
sex, and HbA1c level at baseline.
We report the ICERs for the 10-, 20-, and 30-year time horizons
and the probability of the intervention being cost effective given a
WTP threshold of £30,000. We also illustrate the decision uncer-
tainty with a scatterplot in the cost-effectiveness plane and a
cost-effectiveness acceptability curve.
Analyses of modeled scenarios were conducted using the
UKPDS outcomes v1.3 model and Microsoft Excel (Redmond,
WA). The article was written according to the Consolidated
Health Economic Evaluation Reporting Standards statement [41].
Sensitivity analysis
In additional analyses, we assumed that not only were the costs
of medication incurred until death, but the total incremental
primary care costs, including costs of consultations and other
primary care services, were also incurred until deathPLE
t¼1
βtotal tð Þ
ð1 þ 0:035Þt
 
:
One-way sensitivity analyses were performed on the main
model for ADDITION-UK with varying treatment costs, utility
decrements, and discount rates using the 30-year simulation
data. The range for the discount rate (0%–5%) was guided by
NICE guidelines suggesting a discount rate of 3.5% as base case
and 1.5% in sensitivity analyses [42]. The range for utility
decrements and unit costs (20% to þ20%) was guided by the
coefﬁcient of variation of parameter estimates that averaged
approximately 8% to 12% in the data sources from which the
input parameters were taken [36,39].
We also adjusted our models to most recently available prices
because relative prices, particularly for medications, might have
changed substantially since 2010. The Personal Social Services
Research Unit Costs of Health and Social Care 2010 and 2015
[43,44], the British National Formulary for 2010 and 2016 [45], and
the NHS trust reference cost schedules for 2009/2010 and 2015/2016
[46,47] were used to retrieve relative price changes for GP and nurse
contacts, for cardiometabolic medications, and for hospitalizations of
diabetes-related complications (see Appendix 4 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2017.05.018).Results
Study Design and Study Population
Baseline characteristics of the total UK sample and of the
weighted Cambridge subsample are presented in Table 2. Themean age of the UK sample was around 61.5 years. No substantial
differences were observed between the UK sample (n ¼ 1024) and
the weighted Cambridge subsample from which empirical cost
data were available (n ¼ 173).
Incremental Costs in ADDITION-Cambridge
The primary care cost components for patients in the intensive
treatment and routine care arm are illustrated in Figure 1.
Respective resource utilization for contact with health care
professionals and medication related to the trial protocol is
illustrated in Appendix 5 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2017.05.018. Most costs are attrib-
utable to contacts with GPs, metabolic and cardioprotective
medication, and other types of medications. The annual costs
for contacts with GPs, nurses, and other health care professionals
and the annual costs for glucose-lowering drugs, blood pressure–
lowering drugs, lipid-lowering drugs, aspirin, other medication,
and diagnostic tests stayed constant or increased over the 5-year
time horizon. Signiﬁcant cost differences between the intensive
treatment arm and the routine care arm were observed only for
glucose-lowering and lipid-lowering drugs.
The mean incremental annual costs of intensive treatment
are presented in Table 3. Total incremental annual costs per
patient over the 5-year time period averaged £92 (βtotal-Cambridge ¼
92.0; SEtotal-Cambridge ¼ 115.4) using a GLM with a Gaussian
distribution and an identity link. Incremental annual costs per
patient for GP/nurse consultations and for metabolic/cardiopro-
tective medication averaged £29 (βconsultation-Cambridge ¼ 29.1;
SEconsultation-Cambridge ¼ 33.0) and £55 (βmedication-Cambridge ¼ 54.6;
SEmedication-Cambridge ¼ 28.5), respectively. The incremental costs
for other services were £6 (β ¼ 5.7; SE ¼ 89.1). About 4% of the
variation in the total incremental costs was explained by the
clustering of patients into surgeries (intraclass correlation coef-
ﬁcient ¼ 0.036). A detailed analysis of the cost pattern over time
showed that the cost difference varied considerably between the
observation years (see Appendix 6 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2017.05.018). Omitting
the weighting factor or performing a complete case analysis
(without imputed observation years) altered the results only
marginally.
Long-Term Cost Effectiveness in ADDITION-UK
Table 4 presents the crude accumulated QALYs and costs
over the 10-, 20-, and 30-year time horizon for ADDITION-UK
and ADDITION-Cambridge. Table 5 presents the adjusted
incremental QALYs, costs, and ICERs for ADDITION-UK and
Fig. 1 – Adjusted means of annual primary care costs according to IT (gray) and RC (black) in years 1–5 (generalized linear
model with a gamma distribution and log link with a main effect for the intervention and for time since diagnosis and an
interaction term between intervention and time; adjusted for sex and age of diagnosis and baseline HbA1c; accounted for
patients being clustered in GP surgeries and observations clustered in patients) no SE is available for the cost difference. CI,
conﬁdence interval; GP, general practitioner; HbA1c, glycated hemoglobin A1c; HCP, health care professional; IT, intensive
treatment; RC, routine care; SE, standard error.
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factor reductions in Leicester [16,35], incremental QALYs
in ADDITION-UK were higher than in ADDITION-Cambridge.Table 3 – Adjusted means of annual primary care costs a
Total Consultations
(ADDITION)
Mean SE Mean SE
IT 906.3 82.2 266.4 23.
RC 814.3 81 237.2 23.
Difference 92
(βtotal
†)
115.4
(SEtotal
†)
29.1
(βconsultation
†)
33
(SEconsu
GP, general practitioner; HbA1c, glycated hemoglobin; IT, intensive treatm
* Generalized linear regression model with a Gaussian distribution and id
diagnosis and an interaction term between intervention and time; adju
patients being clustered in GP surgeries and observations clustered in
† Estimate used for long-term cost-effectiveness model.Nevertheless, because of higher implementation costs in Leices-
ter incremental costs in ADDITION-UK were higher than in
ADDITION-Cambridge. Resulting ICER point estimates for theccording to IT and RC in the years 1–5*.
Medication
(ADDITION)
Other
primary care
services
Mean SE Mean SE
2 182.1 19.9 454.1 63.8
5 127.6 20.4 448.3 62.3
ltation
†)
54.6
(βmedication
†)
28.5
(SEmedication
†)
5.7 89.1
ent; RC, routine care; SE, standard error.
entitiy link with a main effect for the intervention and for time since
sted for sex and age of diagnosis and baseline HbA1c; accounted for
patients; model based on 841 observation years from 173 patients.
Table 4 – Crude cumulative cost and QALYs according to IT and RC.
Time horizon RC IT
Crude costs Crude QALYs Crude costs Crude QALYs
n Mean SE Mean SE n Mean SE Mean SE
ADDITION-UK (Leicester and Cambridge)
10 y 501 6,157 332 6.45 0.08 498 7,256 879 6.40 0.09
20 y 501 11,175 867 9.32 0.21 498 12,392 1,614 9.16 0.23
30 y 501 13,181 1,325 10.08 0.30 498 14,308 2,110 9.82 0.31
ADDITION-Cambridge
10 y 501 6,228 341 6.42 0.08 498 7,199 77,265 6.39 0.09
20 y 501 11,208 885 9.21 0.22 498 12,291 149,687 9.11 0.23
30 y 501 13,102 1,324 9.89 0.31 498 14,170 197,961 9.76 0.31
IT, intensive treatment; QALY, quality-adjusted life-year; RC, routine care; SE, standard error.
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QALY, and £27,549/QALY for ADDITION-UK and £96,570/QALY,
£36,115/QALY, and £29,588/QALY, for ADDITION-Cambridge.
Figure 2 shows the scatterplot of the 10-, 20-, and 30-year
QALY and cost pairs of bootstrap replications in the cost-
effectiveness plane and the cost-effectiveness acceptability
curve. For all three time horizons, most of the points lie in the
northeast quadrant. For ADDITION-UK 0.7%, 53.5%, and 56.0%
and for ADDITION-Cambridge 0.9%, 39.5% and 50.0% are posi-
tioned below the £30,000/QALY WTP threshold.Sensitivity Analyses
Incorporating total incremental primary care costs, including
costs of consultations and other primary care services, yielded
a 30-year ICER point estimate of £33,000/QALY for ADDITION-UK
and of £38,000/QALY for ADDITION-Cambridge. The one-way
sensitivity analysis with varying unit costs, discount rates, and
utility decrement for ADDITON-UK is illustrated in the tornado
diagram of Figure 3. It shows that for the speciﬁed ranges the
ICER point estimate for ADDITION-UK lies close to or below the
threshold of £30,000/QALY. Results from the sensitivity analysis
for ADDITION-Cambridge are similar (not shown). Between 2010
and 2015/2016, relative prices increased by 44% for GP and nurse
contacts and by 15% for unit costs for the treatment of diabetes
complications, and they decreased by 41% for relevant cardio-
metabolic medications (see Appendix 4 in SupplementalTable 5 – Adjusted incremental costs and QALYs and ICE
Time horizon Adjusted incremental cost (95% CI) Ad
ADDITION-UK (Leicest
10 y 1,021 (920 to 1,120)
20 y 1,217 (1,029 to 1,406)
30 y 1,311 (1,072 to 1,559)
ADDITION-Ca
10 y 927 (831 to 1,017)
20 y 1,086 (909 to 1,268)
30 y 1,157 (908 to 1,414)
CI, conﬁdence interval; HbA1c, glycated hemoglobin; ICER, incremen
standard error.
* Means and SEs of QALYs and costs at patient level were used to conduc
sex, and HbA1c level at baseline.
† Probability that the ICER is o£30,000/QALY.Materials). The price change–adjusted models resulted in ICERs
of £25,000/QALY for ADDITION-UK and £27,000/QALY for
ADDITION-Cambridge.Discussion
There is uncertainty about the costs and the cost effectiveness of
early intensive multifactorial treatment as delivered in the ADDI-
TION trial. On the basis of electronic primary care records of a
subsample of the trial cohort, we analyzed the incremental costs
of delivered intensive treatment in ADDITION-Cambridge. Follow-
ing an iterative framework of decision making in health care, we
used these empirical cost estimates to update the previously
published cost-effectiveness analysis for ADDITION-UK and
present estimates for ADDITION-Cambridge. The results
show that the intervention was delivered at lower costs than
previously assumed and that there is a moderate likelihood that
the intervention will be cost effective over a time horizon of
30 years.
The difﬁculty of decision making in the context of chronic
diseases is that potential positive effects of treatment, that is,
reduction in cardiovascular events and premature death, are
likely to occur far from the time when interventions are delivered
to patients. This issue is of particularly high relevance for
interventions that target populations at a very early stage in
disease progression, as in the case of treatment for individualsR*.
justed incremental QALYs (95% CI) ICER (£) P†
er and Cambridge)
0.0143 (0.0015 to 0.0294) 71,232 0.007
0.0428 (0.0034 to 0.0817) 28,444 0.535
0.0476 (0.0011 to 0.0932) 27,549 0.560
mbridge
0.0096 (0.0079 to 0.0267) 96,570 0.009
0.0301 (0.0144 to 0.0708) 36,115 0.395
0.0391 (0.0107 to 0.0892) 29,588 0.500
tal cost-effectiveness ratio; QALY, quality-adjusted life-year; SE,
t a bootstrap analysis (n ¼ 500) adjusting for center, age at diagnosis,
Fig. 2 – Cost-effectiveness planes showing pairs of 10-, 20-, and 30-year incremental costs and QALYs from bootstrap samples,
and cost-effectiveness acceptability curves showing the probability of IT being more cost effective than RC on the basis of net
beneﬁt values from bootstrap samples over a time horizon of 10, 20, and 30 y. IT, intensive treatment; QALY,
quality-adjusted life-year; RC, routine care.
V A L U E I N H E A L T H 2 0 ( 2 0 1 7 ) 1 2 8 8 – 1 2 9 8 1295with type 2 diabetes detected by screening. Because decisions in
health care often need to be made promptly and cannot be
postponed until evidence from long-term trials is available,Fig. 3 – Tornado diagram showing the inﬂuence of changing dif
cost-effectiveness modeling analysis. Choice of discount rate ha
costs, and lower utility decrements all associated with higher pomodels that simulate the natural course of the disease, and with
it the expected effects (QALYs) and costs, have been established
as helpful tools [48]. Simulation models, however, rely on a set offerent parameters that contribute to the ICER in long-term
s the greatest impact on the ICER (higher discount rate, unit
int estimate ICER). ICER, incremental cost-effectiveness ratio.
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results of the simulation.
To assess the cost effectiveness of the ADDITION interven-
tion, we previously used the UKPDS outcomes model, which
projects accumulated QALYs and costs over a 10-, 20-, and
30-year time horizon. This analysis showed that ICERs were only
moderately sensitive to the used input parameters (unit costs for
treatment of events, utility decrements for events, and discount
rate), but highly sensitive to the assumptions on the costs of the
intervention itself [17]. The input parameter for the incremental
treatment costs was solely estimated on the trial protocol
assuming 100% protocol adherence. To receive an empirical,
trial-informed estimate, we therefore analyzed the electronic
primary care records of a subset of the ADDITION-Cambridge
trial cohort and used these data to update the long-term cost-
effectiveness model.
The results of the empirical analysis show that the incremen-
tal per-patient costs for actually delivered consultations were
lower than expected (£145 empirical vs. £311 protocol-based for
years 1–5), but that the assumption for extra medication was
appropriate (£54.6 empirical vs. £52.5 protocol- based annually;
see Table 1). The former suggests that GPs did see their patients
more often, but not to the extent for which they were reimbursed
within the trial. The latter indicates that incremental costs for
medication actually delivered were as high as the per-protocol
estimated costs, which were based on the assumption of 100%
protocol adherence with generic drug agents. This is surprising
because we know that the protocol adherence was not perfect
[18]. A possible explanation for this ﬁnding is that the reduction
in costs resulting from the suboptimal medication adherence has
been canceled out by an increase in costs resulting from the high
usage of nongeneric drugs observed in both treatment arms. In
more detailed analyses, for example, we observed that after the
year 2003 when simvastatin went off patent, more than 35% of
statin prescriptions were still for the much more expensive
atorvastatin. Of note, costs for primary care services that were
not directly related to the trial protocol were almost equal in both
trial arms.
Revisiting the previously developed robust evaluation frame-
work [17] with the empirical trial–informed cost estimates shows
that the intervention has a moderate likelihood of being cost-
effective over a time horizon of 30 years, assuming the higher UK
NICE WTP threshold of £30,000/QALY. Our sensitivity analyses
also indicated that the intervention might be cost effective with
most recent prices.
This study also shows that empirical information on the
incremental costs of the delivered intervention is invaluable for
the economic evaluation of this trial. Unknown protocol adher-
ence and the magnitude of generic drug usage can lead to a
considerable over- or underestimation of incremental costs. Tria-
lists should consider whether there could be value in measuring
adherence to protocol when designing future pragmatic studies.
Comparison with the Initial Cost-Effectiveness Analysis
The cost-effectiveness analysis in this study is based on a
previously developed modeling framework [17]. A few minor
methodological adaptations, however, have been made. Sup-
ported by the empirical data, annual costs for extra consultations
in ADDITION-Cambridge were assumed to occur until year 5 and
not only until year 3. Furthermore, the uncertainty of incremental
costs was considered in the cost-effectiveness model by incor-
porating the SEs of the empirically derived incremental cost
estimates in an additive manner. In the initial long-term cost-
effectiveness analysis we also erroneously presumed that the
mean costs for additional medication would be incurred until the
end of the 10-, 20-, and 30-year simulation time horizonindependently of individual simulated deaths of participants
[17]. In this study, we took the more plausible assumption that
costs for extra medication will occur until a person dies or
reaches the end of the simulated time horizon. Applying this
assumption to the previous cost-effectiveness analyses would
have led to ICER point estimates of around £83,000/QALY,
£32,000/QALY, and £30,000/QALY for a 10-, 20-, and 30-year
simulation time horizon, respectively. The decrease in the ICER
in our study can be explained by the lower frequency of extra
consultations compared with the per-protocol assumed costs in
the ADDITION-Cambridge sample (see Table 1).
Strengths and Limitations
The main strength of this study is the use of empirical data from
electronic primary care records from a subsample of the
ADDITION-Cambridge trial sample. The use of these data pro-
vided a unique insight into the cost structure of intensive treat-
ment as delivered in the ADDITION trial and allowed us to
perform a detailed analysis of incremental cost components.
This allowed us to revisit the cost-effectiveness analyses with
the updated cost estimates using a previously developed robust
evaluation framework and incorporated the uncertainty around
the empirically derived cost estimates.
There are also some limitations that need to be taken into
account. First and most importantly, the risk equations of the
UKPDS outcomes model v1.3 were derived from a historical
cohort followed from 1977 to 1997. Because the general quality
of diabetes care has improved since then, the model overesti-
mates the absolute cardiovascular disease risk in current pop-
ulations. This ﬁnding was replicated in a previous validation
study based on ADDITION data. Nevertheless, this validation
study also showed that the model performed reasonably well in
the prediction of incremental cardiovascular event rates in the
ADDITION-UK sample [34]. Second, the input parameters for
costs and utility decrements associated with the modeled events
might be outdated und updating for inﬂation will not account for
changes in relative prices. We therefore performed sensitivity
analyses on these parameters, which showed that the results
were only moderately sensitive toward variation in these param-
eters. Third, we had empirical information on primary care costs
for only about 20% of the ADDITION-Cambridge trial cohort. We
therefore kept the protocol-based assumptions for participants
from Leicester in the analysis for ADDITION-UK, but performed
separate analyses restricted to ADDITION-Cambridge partici-
pants. We further assigned mean cost estimates instead of
individual-level costs to patients from Cambridge and Leicester.
Fourth, because of the relatively small sample size, the clustering
of patients into GP practices, and the nonavailability of informa-
tion on resource utilization before randomization, the uncer-
tainty around the cost estimates remained relatively large. Fifth,
we had only empirical information on primary care contacts. We
therefore used the risk factor proﬁle of participants together with
the UKPDS outcomes model to predict complications and costs
(including hospital costs) associated with those complications.
Nevertheless, we do not know whether the intervention provoked
or prevented other unexpected care use that is not captured by
the model and also not by our empirical primary care cost
analyses. This shortcoming could have biased the cost estimates
and ICERs in either direction. Sixth, we estimated incremental
costs for medication on the basis of prescriptions issued. We,
however, do not know how many of these were actually dis-
pensed and we therefore probably overestimated the absolute
(and incremental) costs for medications. Other limitations, such
as the fact that the UKPDS outcomes model does not incorporate
all diabetes-related complications and that the ADDITION-UK
sample does not adequately represent UK ethnic diversity,
V A L U E I N H E A L T H 2 0 ( 2 0 1 7 ) 1 2 8 8 – 1 2 9 8 1297limiting its external validity, have been discussed in detail by Tao
et al. [17].Conclusions
Revisiting and correcting the initial cost-effectiveness analyses
with empirical trial–informed cost estimates suggests that money
spent on intensive treatment in individuals with type 2 diabetes
detected by screening might be borderline cost effective accord-
ing to conventional UK WTP thresholds. Nevertheless, the results
need to be interpreted with caution because the projection of trial
data over a long time horizon is almost always associated with
substantial uncertainty.Acknowledgments
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